About 50% of patients with CLL/SLL have high-risk molecular features limiting effectiveness of certain treatments; a blood test can identify these features and help guide which therapy is most likely ...

About 50% of patients with CLL/SLL have high-risk molecular features limiting effectiveness of certain treatments; a blood test can identify these features and help guide which therapy is most likely ...

Patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphomas (NHLs) who received frequent tests for immunoglobulin G (IgG) were less likely to experience severe infections compared with ...

How well a certain treatment for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) works can vary greatly depending on the makeup of an individual patient’s disease, making ...

Open-Source Hybrid Large Language Model Integrated System for Extraction of Breast Cancer Treatment Pathway From Free-Text Clinical Notes The diagnosis of chronic lymphocytic leukemia (CLL) is often ...

Chronic myeloid leukemia (CML) and chronic lymphocytic leukemia (CLL) are two different types of leukemia. Both conditions affect white blood cells. CML affects a type of white blood cell called ...

Identification of recurrent genetic abnormalities is important for disease evaluation, optimal risk stratification and treatment planning. Testing for recurrent genetic abnormalities should be ...

Chronic lymphocytic leukemia (CLL) and prolymphocytic leukemia (PLL) are types of blood cancer. They develop in types of white blood cells called B cells or T cells, or the precursors to these cells.

Chronic lymphocytic leukemia (CLL) does not always cause symptoms in the beginning. They may not appear until the condition advances. When CLL symptoms do develop, they can include swollen lymph nodes ...